Overview

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.

Phase:

PHASE2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

mirikizumab